Literature DB >> 6252831

Comparison of cefoperazone, cefotaxime, and moxalactam (LY127935) against aerobic gram-negative bacilli.

S D Lang, D J Edwards, D T Durack.   

Abstract

This study compares the minimum inhibitory concentrations of cefoperazone, cefotaxime, and moxalactam (LY127935) for 446 aerobic gram-negative bacillary isolates and further compares the minimum inhibitory concentrations of LY127935 and these third-generation cephalosporins with those of thienamycin for Pseudomonas aeruginosa. Each antibiotic at low concentrations inhibited nearly all Enterobacteriaceae tested. Minimum inhibitory concentrations for P. aeruginosa were higher, but for a majority of strains they fell below achievable serum levels. Thienamycin and cefoperazone showed significantly greater antipseudomonal activity than did cefotaxime or LY127935. Cefoxitin-inducible resistance to LY127935 and the two cephalosporins was demonstrated among Enterobacter species but did not occur with thienamycin.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6252831      PMCID: PMC283815          DOI: 10.1128/AAC.17.3.488

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Thienamycin: new beta-lactam antibiotic with potent broad-spectrum activity.

Authors:  S S Weaver; G P Bodey; B M LeBlanc
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

2.  Antibacterial activity of a new parenteral cephalosporin--HR 756: comparison with cefamandole and ceforanide.

Authors:  G W Counts; M Turck
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

3.  Diffusion disk susceptibility testing with cefotaxime.

Authors:  N Aswapokee; P Aswapokee; H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

4.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

5.  Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin.

Authors:  H C Neu; K P Fu; N Aswapokee; P Aswapokee; K Kung
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

6.  Emergence of resistance to cefamandole: possible role of cefoxitin-inducible beta-lactamases.

Authors:  C C Sanders; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1979-06       Impact factor: 5.191

7.  HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria.

Authors:  H C Neu; N Aswapokee; P Aswapokee; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

8.  In vitro of cefotaxime against cephalothin-resistant clinical isolates.

Authors:  H W Van Landuyt; M Pyckavet
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

9.  Dissociated resistance among cephalosporins.

Authors:  P M Waterworth; A M Emmerson
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

  9 in total
  29 in total

Review 1.  Seventy-Five Years of Research on Protein Binding.

Authors:  Axel Dalhoff
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

2.  Determination of cefoperazone concentration in serum and muscle tissue with a versatile high-pressure liquid chromatographic method.

Authors:  R R Muder; W F Diven; V L Yu; J Johnson
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

3.  Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.

Authors:  R Lüthy; J Blaser; A Bonetti; H Simmen; R Wise; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

4.  Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.

Authors:  B Kemmerich; H Lode; G Belmega; T Jendroschek; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

5.  Susceptibility of clinical isolates to cefoperazone.

Authors:  D A Bremner
Journal:  Drugs       Date:  1981       Impact factor: 9.546

6.  Anomalous effect of serum on the antimicrobial activity of cefoperazone.

Authors:  S D Lang; G L Cameron; P R Mullins
Journal:  Drugs       Date:  1981       Impact factor: 9.546

7.  In vitro activity of cefotaxime against clinically significant pathogens.

Authors:  S Nakashio; M Nakamura
Journal:  Drugs       Date:  1988       Impact factor: 9.546

8.  Comparison of cefotaxime, imipenem-cilastatin, ampicillin-gentamicin, and ampicillin-chloramphenicol in the treatment of experimental Escherichia coli bacteremia and meningitis.

Authors:  K S Kim
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

9.  Clinical efficacy of cefotaxime in serious infections.

Authors:  P H Karakusis; J M Feczko; L J Goodman; D M Hanlon; A A Harris; S Levin; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

10.  Comparative in vitro synergistic activity of new beta-lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens.

Authors:  T O Kurtz; D J Winston; D A Bruckner; W J Martin
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.